Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer

• Published in: Frontiers in oncology Vol. 10; p. 592501
• Main Authors: Rong, Chao, Zhou, Ran, Wan, Shan, Su, Dan, Wang, Shou-Li, Hess, Jochen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.01.2021
• Subjects: clinical relevance; deubiquitinating enzymes; genomic alteration; head and neck cancer; Oncology; ubiquitin C-terminal hydrolases; ubiquitin C-terminal hydrolases; head and neck cancer; genomic alteration; deubiquitinating enzymes; clinical relevance
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.592501

Ubiquitin C-terminal hydrolases (UCHs), a subfamily of deubiquitinating enzymes (DUBs), have been found in a variety of tumor entities and play distinct roles in the pathogenesis and development of various cancers including head and neck cancer (HNC). HNC is a heterogeneous disease arising from the mucosal epithelia of the upper aerodigestive tract, including different anatomic sites, distinct histopathologic types, as well as human papillomavirus (HPV)-positive and negative subgroups. Despite advances in multi-disciplinary treatment for HNC, the long-term survival rate of patients with HNC remains low. Emerging evidence has revealed the members of UCHs are associated with the pathogenesis and clinical prognosis of HNC, which highlights the prognostic and therapeutic implications of UCHs for patients with HNC. In this review, we summarize the physiological and pathological functions of the UCHs family, which provides enlightenment of potential mechanisms of UCHs family in HNC pathogenesis and highlights the potential consideration of UCHs as attractive drug targets.